ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia.
Leukemia
Schönfeld, Lioba L; Rinke, Jenny J; Hinze, Anna A; Nagel, Saskia N SN; Schäfer, Vivien V; Schenk, Thomas T; Fabisch, Christian C; Brümmendorf, Tim H TH; Burchert, Andreas A; le Coutre, Philipp P; Krause, Stefan W SW; Saussele, Susanne S; Safizadeh, Fatemeh F; Pfirrmann, Markus M; Hochhaus, Andreas A; Ernst, Thomas T
Context dependent effects of ascorbic acid treatment in TET2 mutant myeloid neoplasia.
Communications Biology
Guan, Yihong Y; Greenberg, Edward F EF; Hasipek, Metis M; Chen, Shi S; Liu, Xiaochen X; Kerr, Cassandra M CM; Gackowski, Daniel D; Zarakowska, Ewelina E; Radivoyevitch, Tomas T; Gu, Xiaorong X; Willard, Belinda B; Visconte, Valeria V; Makishima, Hideki H; Nazha, Aziz A; Mukherji, Mridul M; Sekeres, Mikkael A MA; Saunthararajah, Yogen Y; Oliński, Ryszard R; Xu, Mingjiang M; Maciejewski, Jaroslaw P JP; Jha, Babal K BK